Gentex Pharma Competitors and Similar CompaniesClear all

Gentex Pharma's competitors and similar companies include TFF Pharmaceuticals, UCB, Genentech and EMS Pharma.

	Gentex Pharma Gentex Pharma is a company focused on providing medications for upper and lower respiratory conditions.	TFF Pharmaceuticals TFF Pharmaceuticals is a biopharmaceutical company focused on developing drug products based on the Thin Film Freezing (TFF) technology platform.	UCB UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions.	Genentech Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines.	EMS Pharma EMS Pharma is a company that specializes in the research, development, and manufacturing of pharmaceuticals.
Founding Date	Founding Date 2005	Founding Date 2018	Founding Date 1928	Founding Date 1976	Founding Date 1964
Type	Type Private	Type Public	Type Public	Type Subsidiary	Type Private
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma platform	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development pharma
Locations	Locations Madison, US HQ	Locations Austin, US HQ	Locations Brussels, BE HQ Melbourne, AU Vienna, AT Braine L'alleud, BE Braine L'alleud, BE Leuven, BE São Paulo, BR see more	Locations South San Francisco, US HQ Hillsboro, US Oceanside, US Portland, US South San Francisco, US South San Francisco, US South San Francisco, US see more	Locations BR HQ
Employees	Employees N/A	Employees 1927% increase	Employees 9,052	Employees 18,077	Employees 12,7441% increase
Valuation ($)	Valuation ($) N/A	Valuation ($) 8.5 m	Valuation ($) 34.3 b	Valuation ($) N/A	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $733.9k (FY, 2023)	Revenue (est.) €7.4b (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A
Net income	Net income N/A	Net income ($21.2m) (FY, 2023)	Net income €1.6b (FY, 2025)	Net income N/A	Net income N/A